The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
The country is sixth among the most affected countries by active cases
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
Previously, the use of the drug was limited to patients requiring hospitalization
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
Go-ahead for pivotal clinical trial which is expected to commence by March
UCB plans to submit regulatory applications in Q3 2022
An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Subscribe To Our Newsletter & Stay Updated
